SCHEMBL2389008

SCHEMBL2389008

C#Cc1ccsc1-c1cc(C(F)(F)F)c(C#N)c(=O)n1Cc1ccc(F)cc1F.c1cc2ccc1-2

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXRA P19793 3/20 0.59
NR1H2 P55055 3/20 0.59
NR1H3 Q13133 3/20 0.59
ALDH1A1 P00352 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 2/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
MAPK14 Q16539 2/20 0.33
POLB P06746 1/20 0.32
RIPK3 Q9Y572 3/20 0.32
CHRM1 P11229 1/20 0.31
TNKS O95271 1/20 0.31
TNKS2 Q9H2K2 1/20 0.31
AR P10275 2/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2389291 0.94 RXRA (0.57) RXRANR1H2NR1H3ALDH1A1KMT2A
SCHEMBL2390073 0.84 RXRA (0.66) RXRANR1H2NR1H3ALDH1A1KMT2A
SCHEMBL14214400 0.80 RXRA (0.84) RXRANR1H2NR1H3ALDH1A1KMT2A
SCHEMBL4902052 0.80 RXRA (0.55) RXRANR1H2NR1H3ALDH1A1KMT2A
SCHEMBL2387983 0.79 RXRA (0.71) RXRANR1H2NR1H3ALDH1A1KMT2A
SCHEMBL2390091 0.79 RXRA (0.62) RXRANR1H2NR1H3ALDH1A1KMT2A
SCHEMBL2391013 0.79 RXRA (0.72) RXRANR1H2NR1H3ALDH1A1KMT2A
SCHEMBL4899639 0.78 RXRA (0.74) RXRANR1H2NR1H3ALDH1A1KMT2A
SCHEMBL2262731 0.78 RXRA (0.83) RXRANR1H2NR1H3ALDH1A1KMT2A
SCHEMBL2387246 0.77 RXRA (0.91) RXRANR1H2NR1H3ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482366-B2 Modulators of LXR X-CEPTOR THERAPEUTICS, INC. (US) 2009-01-27 US claimed
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US claimed
EP-1773337-A2 MODULATORS OF NUCLEAR RECEPTORS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006025979-A2 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS, INC. (US) 2006-03-09 WO claimed
US-20050080111-A1 Modulators of LXR X-CEPTOR THERAPEUTICS, INC. (US) 2005-04-14 US claimed
US-8013001-B2 Modulators of LXR EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-20100056582-A1 Modulators of LXR X-CEPTOR THERAPEUTICS, INC. (US) 2010-03-04 US disclosed
US-7482366-B2 Modulators of LXR X-CEPTOR THERAPEUTICS, INC. (US) 2009-01-27 US disclosed
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US disclosed
US-20050080111-A1 Modulators of LXR X-CEPTOR THERAPEUTICS, INC. (US) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119488-A1 Modulators Of Nuclear Receptors NR1H2, NR0B1, NR1H3 RXRA 20/4885NR1H2 1/4885NR1H3 3/4885
US-20050080111-A1 Modulators of LXR NR1H2, NR1H3, NR1H4 RXRA 16/4885NR1H2 1/4885NR1H3 2/4885
US-20100056582-A1 Modulators of LXR NR1H2, NR1H3, NR1H4 RXRA 16/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.